Biomarker and pathogenicity claims for antiphospholipid antibodies in post-treatment Lyme disease syndrome
Infection and Immunity · 10.11.2026 · 94 (11)
DOI: 10.1128/iai.00436-26 ↗Kurz gefasst
Leserbrief in der Zeitschrift Infection and Immunity, erschienen am 10.11.2026. Verfasst von Armin Alaedini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
- Division of Infectious Diseases, Department of Medicine, New York Medical College, Valhalla, New York, USA.
- Inflammation and Autoimmunity Research Program, Hospital for Special Surgery and Weill Cornell Medicine, New York, New York, USA.
ORCID-Profile: Armin Alaedini, Gary P Wormser, Mary K Crow
Zitieren
APA
Alaedini, A., Wormser, G. P., & Crow, M. K. (2026). Biomarker and pathogenicity claims for antiphospholipid antibodies in post-treatment Lyme disease syndrome. Infection and Immunity, 94(11). https://doi.org/10.1128/iai.00436-26
Vancouver
Alaedini A, Wormser GP, Crow MK. Biomarker and pathogenicity claims for antiphospholipid antibodies in post-treatment Lyme disease syndrome. Infection and Immunity. 2026;94(11). doi:10.1128/iai.00436-26
BibTeX
@article{Alaedini2026,
author = {Alaedini, Armin and Wormser, Gary P and Crow, Mary K},
title = {Biomarker and pathogenicity claims for antiphospholipid antibodies in post-treatment Lyme disease syndrome},
journal = {Infection and Immunity},
year = {2026},
volume = {94},
number = {11},
doi = {10.1128/iai.00436-26}
}
EUVIMED